跳至主要内容
临床试验/ISRCTN17415294
ISRCTN17415294已完成2 期

Randomised double-blind controlled phase II trial of Tocovid SupraBio in combination with pentoxifylline (PTX) in patients suffering long-term adverse effects of radiotherapy for pelvic cancer

Royal Marsden NHS Foundation Trust0 个研究点目标入组 62 人开始时间: 2015年1月12日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
62

研究概览

简要总结

2022 Results article in https://doi.org/10.1016/j.radonc.2022.01.024 (added 11/02/2022)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age over 18 years.
  • 2. Past history of a malignant pelvic neoplasm (T14 N02 M0) of the rectum, prostate, testis, bladder, uterine cervix, uterus, vagina, anal canal or ovary.
  • 3. A minimum 12 months followup postradiotherapy (24 months for patients with past history of stage T4 and/or N2 disease)
  • 4. A maximum 7 years postradiotherapy
  • 5. No evidence of cancer recurrence
  • 6. Gastrointestinal symptoms attributable to prior radiotherapy: grade 2 or higher in any CTCAE Version 4 category, or grade 1 with difficult intermittent symptoms
  • 7. Symptoms are not relieved by appropriate lifestyle advice and medication over a 3 month period
  • 8. Physical and psychological fitness for Tocovid SupraBio+PTX therapy
  • 9. Written informed consent and availability for follow up
  • 10. Willingness to keep to a specified level of dietary fat intake during the study
  • 11. Symptoms are not relieved by appropriate life-style advice and medication over a 3-month period after optimal gastroenterological assessment

排除标准

  • 1. Surgery for rectal cancer
  • 2. Contraindication or other inability to undergo magnetic resonance imaging, if required to rule out malignancy
  • 3. Dietary supplementation containing alphatocopherol above a daily dose of 30mg at any time during the last three months
  • 4. Medication with pentoxifylline at any time since radiotherapy
  • 5. Pregnancy or breast feeding
  • 6. Ischaemic heart disease, uncontrolled hypertension, hypotension, acute myocardial infarction, cerebral haemorrhage, retinal haemorrhage, renal failure, liver failure and medication with insulin, ketorolac or vitamin K
  • 7. Allergy to soya
  • 8. Known hypersensitivity to the active constituent, pentoxifylline other methyl xanthines or any of the excipients’, as per SmPC for pentoxifylline

研究者

相似试验